Merck & Co earnings were $16.4B for the trailing 12 months ending Jun 30, 2025, with 20.1% growth year over year. The latest MRK earnings report on Jun 30, 2025 announced Q2 2025 earnings of $4.4B, down 12.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRK reported annual earnings of $17.1B, with 4,589.6% growth.
MRK past earnings growth
How has MRK's earnings growth performed historically?
On MRK's earnings call on Invalid Date, Merck & Co (NYSE: MRK) reported Q2 2025 earnings per share (EPS) of $1.76, up 18.14% year over year. Total MRK earnings for the quarter were $4.43 billion. In the same quarter last year, Merck & Co's earnings per share (EPS) was $2.15.
As of the last Merck & Co earnings report, Merck & Co is currently profitable. Merck & Co's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $16.41 billion, a 19.44% increase year over year.
What was MRK's earnings growth in the past year?
As of Merck & Co's earnings date in Invalid Date, Merck & Co's earnings has grown 20.15% year over year. This is 29.97 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 50.12%. MRK earnings in the past year totalled $16.41 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.